Picture of Coherus Biosciences logo

CHRS Coherus Biosciences Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Annual income statement for Coherus Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue356476327211257
Cost of Revenue
Gross Profit33943826914198.3
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses248320590474460
Operating Profit108156-264-263-203
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes92.8136-287-292-238
Provision for Income Taxes
Net Income After Taxes89.8132-287-292-238
Minority Interest
Net Income Before Extraordinary Items
Net Income89.8132-287-292-238
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income89.8136-287-292-238
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS1.231.62-3.81-3.68-2.46